Literature DB >> 8193405

Rapid diagnosis of Chlamydia trachomatis with a nucleic acid probe in male and female patients.

A Stary1, W Kopp, B Zahel, I Müller, S Nerad, M Storch.   

Abstract

To evaluate a commercially available DNA hybridization test, the Gen-Probe Pace 2 assay (GP) was compared with the Chlamydiazyme (CZ) for the detection of Chlamydia trachomatis in urethral and endocervical specimens. Samples were collected from 300 persons, including 199 registered and 43 nonregistered female prostitutes, examined for screening purposes, as well as 22 male and 36 female symptomatic sexually transmitted disease (STD) patients. The overall prevalence of C. trachomatis was 7.3% in all persons examined with an infection rate of 20.9% in the nonregistered prostitutes, 2.5% in the registered prostitutes and 13.8% in the STD patients. The overall concordance of both diagnostic methods was 98.7% in all samples examined, 100% in male and 98.6% in female samples. Specimens with discordant results were further analyzed by a direct immunofluorescence test (MicroTrak) and by the probe competition assay (PCA). All samples only positive in the GP assay could be confirmed by the PCA while one result which was positive in the CZ could not be confirmed by any other test. The GP assay was superior to the CZ, when compared with true-positive and -negative results. The data demonstrate that the GP assay can be recommended as an alternative diagnostic technique to the CZ for Chlamydia diagnosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8193405     DOI: 10.1159/000247171

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  5 in total

1.  Performance characteristics of the Gen-Probe Probe Competition Assay used as a supplementary test for the Gen-Probe PACE 2 and 2C assays for detection of Chlamydia trachomatis.

Authors:  J L Beebe; T R Sharpton; S N Zanto; R S Steece; C Rogers; S L Mottice
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

2.  Detection of Chlamydia trachomatis by the Gen-Probe AMPLIFIED Chlamydia Trachomatis Assay (AMP CT) in urine specimens from men and women and endocervical specimens from women.

Authors:  K A Crotchfelt; B Pare; C Gaydos; T C Quinn
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

3.  Periodic health examination, 1996 update: 2. Screening for chlamydial infections. Canadian Task Force on the Periodic Health Examination.

Authors:  H D Davies; E E Wang
Journal:  CMAJ       Date:  1996-06-01       Impact factor: 8.262

4.  Detection of Chlamydia trachomatis in urethral and urine samples from symptomatic and asymptomatic male patients by the polymerase chain reaction.

Authors:  A Stary; B Choueiri; I Hörting-Müller; P Halisch; L Teodorowicz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

5.  Evaluation of nucleic acid-based test (PACE 2C) for simultaneous detection of Chlamydia trachomatis and Neisseria gonorrhoeae in endocervical specimens.

Authors:  P C Iwen; R A Walker; K L Warren; D M Kelly; S H Hinrichs; J Linder
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.